AR036315A1 - Vacuna para la aterosclerosis con fragmentos de apociii, anticuerpos anti apociii - Google Patents
Vacuna para la aterosclerosis con fragmentos de apociii, anticuerpos anti apociiiInfo
- Publication number
- AR036315A1 AR036315A1 ARP020103263A ARP020103263A AR036315A1 AR 036315 A1 AR036315 A1 AR 036315A1 AR P020103263 A ARP020103263 A AR P020103263A AR P020103263 A ARP020103263 A AR P020103263A AR 036315 A1 AR036315 A1 AR 036315A1
- Authority
- AR
- Argentina
- Prior art keywords
- apociii
- fragments
- immunogens
- atherosclerosis
- specific
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 102100030970 Apolipoprotein C-III Human genes 0.000 title 2
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 title 2
- 102000030169 Apolipoprotein C-III Human genes 0.000 abstract 5
- 108010056301 Apolipoprotein C-III Proteins 0.000 abstract 5
- 201000001320 Atherosclerosis Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente se refiere a nuevas terapias de vacuna y a tratamientos profilácticos de enfermedades ateroscleróticas. Como consecuencia, se proporcionan inmunógenos que comprenden fragmentos o derivados específicos de apolipoproteína C-III (ApoCIII). Las vacunas de la presente, que comprenden los citados inmunógenos, son potentes en la prevención o reducción de la formación de placa aterosclerótica durante periodos prolongados de tiempo, reduciendo así el potencial de aterosclerosis que conduce a enfermedades coronarias o cerebrovasculares. Se proporcionan también procedimientos de tratamiento o prevención de la aterosclerosis por vacunación activa, o vacunación pasiva mediante la administración a un paciente de un anticuerpo que sea capaz de unirse a fragmentos específicos de ApoCIII. Se proporcionan los anticuerpos monoclonales específicos y su uso en terapia de la aterosclerosis. Se proporciona adicionalmente el uso de los inmunógenos de la presente en medicina, y procedimientos para su producción. Los fragmentos de ApoCIII que forman la base de los inmunógenos de la presente, y también las dianas para la inmunoterapia pasiva, están comprendidos dentro de las regiones entre los aminoácidos número 45-76, y particularmente 12-35, de la forma madura de la ApoCIII humana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0121171.3A GB0121171D0 (en) | 2001-08-31 | 2001-08-31 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036315A1 true AR036315A1 (es) | 2004-08-25 |
Family
ID=9921337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103263A AR036315A1 (es) | 2001-08-31 | 2002-08-29 | Vacuna para la aterosclerosis con fragmentos de apociii, anticuerpos anti apociii |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20040253240A1 (es) |
| EP (1) | EP1421116A2 (es) |
| JP (1) | JP2005508900A (es) |
| AR (1) | AR036315A1 (es) |
| AU (1) | AU2002324073A1 (es) |
| CA (1) | CA2458237A1 (es) |
| GB (1) | GB0121171D0 (es) |
| WO (1) | WO2003020765A2 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005502618A (ja) | 2001-06-04 | 2005-01-27 | ザ・ジェネラル・ホスピタル・コーポレイション | 光力学的化合物を用いて脆弱なプラークを検出および治療する方法 |
| GB0305794D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0305793D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0305790D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Novel Composition |
| ES2398110T3 (es) * | 2003-04-29 | 2013-03-13 | Biocrine Ab | ApoCIII y tratamiento y diagnóstico de la diabetes |
| CA2549529A1 (en) * | 2003-12-15 | 2005-06-30 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| US20090035446A1 (en) * | 2005-09-06 | 2009-02-05 | Theraject, Inc. | Solid Solution Perforator Containing Drug Particle and/or Drug-Adsorbed Particles |
| WO2007051077A2 (en) * | 2005-10-28 | 2007-05-03 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
| AU2007300842B2 (en) | 2006-09-25 | 2011-01-27 | Sj Biomed Inc. | Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same |
| CU23736A1 (es) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
| NZ620441A (en) * | 2009-09-03 | 2015-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| AU2012249324B2 (en) * | 2011-04-27 | 2016-10-06 | Ionis Pharmaceuticals, Inc. | Modulation of apolipoprotein CIII (ApoCIII) expression |
| EP2958628A4 (en) * | 2013-02-25 | 2016-11-23 | Imetabolic Biopharma Llc | APOLIPOPROTEIN C3 ANTAGONISTS (APOCIII) AND METHODS OF USING THEM TO UPHALT APOCIII INHIBITION OF LIPOPROTEIN LIPASE (LPL) |
| KR20190039937A (ko) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | 항-ApoC3 항체 및 이의 사용 방법 |
| AU2018255938A1 (en) * | 2017-04-21 | 2019-10-31 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| CN111315772A (zh) * | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| EP4237561A1 (en) | 2020-12-23 | 2023-09-06 | Argonaute Rna Limited | Treatment of cardiovascular disease |
| WO2023041508A2 (en) | 2021-09-14 | 2023-03-23 | Argonaute RNA Limited | Treatment of cardiovascular disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668629A (en) * | 1980-07-18 | 1987-05-26 | The Board Of Trustees Of Leland Stanford Jr. University | Human hybridomas, precursors and products |
| WO1986004144A1 (en) * | 1984-12-31 | 1986-07-17 | International Genetic Engineering, Inc. | Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use |
| US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US6492185B1 (en) * | 1998-01-16 | 2002-12-10 | Abbott Laboratories | Immunoassay for detection of very low density lipoprotein and antibodies useful therefor |
| JP4240165B2 (ja) * | 1998-11-10 | 2009-03-18 | 堺化学工業株式会社 | 血小板由来白血球貪食能亢進因子の活性化因子 |
| JP2003525883A (ja) * | 2000-03-03 | 2003-09-02 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
-
2001
- 2001-08-31 GB GBGB0121171.3A patent/GB0121171D0/en not_active Ceased
-
2002
- 2002-08-29 WO PCT/EP2002/009650 patent/WO2003020765A2/en not_active Application Discontinuation
- 2002-08-29 US US10/488,219 patent/US20040253240A1/en not_active Abandoned
- 2002-08-29 AR ARP020103263A patent/AR036315A1/es unknown
- 2002-08-29 CA CA002458237A patent/CA2458237A1/en not_active Abandoned
- 2002-08-29 JP JP2003525035A patent/JP2005508900A/ja active Pending
- 2002-08-29 EP EP02758487A patent/EP1421116A2/en not_active Withdrawn
- 2002-08-29 AU AU2002324073A patent/AU2002324073A1/en not_active Abandoned
-
2003
- 2003-03-13 US US10/387,934 patent/US20040091496A1/en not_active Abandoned
- 2003-07-15 US US10/387,955 patent/US20040185044A1/en not_active Abandoned
- 2003-08-20 US US10/387,957 patent/US20040052809A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040253240A1 (en) | 2004-12-16 |
| JP2005508900A (ja) | 2005-04-07 |
| AU2002324073A1 (en) | 2003-03-18 |
| WO2003020765A3 (en) | 2003-08-14 |
| WO2003020765A2 (en) | 2003-03-13 |
| US20040052809A1 (en) | 2004-03-18 |
| CA2458237A1 (en) | 2003-03-13 |
| EP1421116A2 (en) | 2004-05-26 |
| GB0121171D0 (en) | 2001-10-24 |
| US20040091496A1 (en) | 2004-05-13 |
| US20040185044A1 (en) | 2004-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036315A1 (es) | Vacuna para la aterosclerosis con fragmentos de apociii, anticuerpos anti apociii | |
| BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
| CY1119369T1 (el) | Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α | |
| BRPI0619747B8 (pt) | método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide | |
| ATE119037T1 (de) | Influenzaimpfstoff und adjuvanten. | |
| EA200400227A1 (ru) | Применение биологически активного тат вич-1, его фрагментов или производных для нацеливания на антигенпредставляющие клетки, и/или их активации, и/ или для доставки карго-молекул для профилактической или терапевтической вакцинации, и/или для лечения других заболеваний | |
| AR027591A1 (es) | Inmunogeno para el tratamiento de la aterosclerosis; vacunas formuladas con dicho inmunogeno y procedimiento para el tratamiento o profilaxis de laaterosclerosis utilizando dicho inmunogeno. | |
| NO20015073L (no) | Vaksiner | |
| Warger et al. | Initiation of adaptive immune responses by transcutaneous immunization | |
| CO6501190A2 (es) | Vacuna de pcsk9 | |
| AR004445A1 (es) | Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada | |
| AR024074A1 (es) | FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS. | |
| CO5280094A1 (es) | Un analogo de a o app y una composicion inmunogenica que comprende dicho analogo | |
| CY1111916T1 (el) | Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος | |
| HUP0203972A2 (hu) | Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra | |
| CY1115407T1 (el) | Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων | |
| Johnston et al. | TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines | |
| Dutta et al. | Immunogenicity and protective potential of a Plasmodium spp. enolase peptide displayed on archaeal gas vesicle nanoparticles | |
| DE60331412D1 (de) | Hiv-vakzine und anwendungsverfahren | |
| AR053661A1 (es) | Peptido para entregar vacunas via mucosas | |
| Rong et al. | Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine | |
| EA201690057A1 (ru) | Остеопонтин молока млекопитающих для повышения иммунологической реактивности | |
| WO2004080375A3 (en) | Vaccine therapy of atherosclerosis | |
| WO2004081045A3 (en) | Vaccine related to modified apolipoprotein c-iii | |
| CA2354045A1 (en) | New cancer treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |